Research programme: GPCR modulators - metabolic disorders - Heptares Therapeutics

Drug Profile

Research programme: GPCR modulators - metabolic disorders - Heptares Therapeutics

Alternative Names: G protein-coupled receptor 39 agonists; G protein-coupled receptor modulators; GLP-1 antagonists; Glucagon-like peptide 1 antagonists; GPR39 modulators

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medical Research Council
  • Developer Heptares Therapeutics; Medical Research Council
  • Class Small molecules
  • Mechanism of Action Glucagon-like peptide 1 receptor modulators; Glucagon-like peptide-1 receptor antagonists; GPR39 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hyperinsulinaemia; Hypoglycaemia
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in United Kingdom (PO)
  • 25 Apr 2016 Early research in Hyperinsulinaemia in United Kingdom (unspecified route)
  • 23 Feb 2015 Heptares Therapeutics has been acquired by Sosei
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top